UNLABELLED: Antimitochondrial antibodies (AMAs) directed against the lipoyl domain of the E2 subunit of pyruvate dehydrogenase (PDC-E2) are detected in 95% of patients with primary biliary cirrhosis (PBC) and are present before the onset of clinical disease. The recent demonstration that AMAs recognize xenobiotic modified PDC-E2 with higher titers than native PDC-E2 raises the possibility that the earliest events involved in loss of tolerance are related to xenobiotic modification. We hypothesized that reactivity to such xenobiotics would be predominantly immunoglobulin M (IgM) and using sera from a large cohort of PBC patients and controls (n = 516), we examined in detail sera reactivity against either 6,8-bis(acetylthio) octanoic acid (SAc)-conjugated bovine serum albumin (BSA), recombinant PDC-E2 (rPDC-E2) or BSA alone. Further, we also defined the relative specificity to the SAc moiety using inhibition enzyme-linked immunosorbent assay (ELISA); SAc conjugate and rPDC-E2-specific affinity-purified antibodies were also examined for antigen specificity, isotype, and crossreactivity. Reactivity to SAc conjugates is predominantly IgM; such reactivity reflects a footprint of previous xenobiotic exposure. Indeed, this observation is supported by both direct binding, crossreactivity, and inhibition studies. In both early and late-stage PBC, the predominant Ig isotype to SAc is IgM, with titers higher with advanced stage disease. We also note that there was a higher level of IgM reactivity to SAc than to rPDC-E2 in early-stage versus late-stage PBC. Interestingly, this finding is particularly significant in light of the structural similarity between SAc and the reduced form of lipoic acid, a step which is similar to the normal physiological oxidation of lipoic acid. CONCLUSION: Specific modifications of the disulfide bond within the lipoic-acid-conjugated PDC-E2 moiety, i.e., by an electrophilic agent renders PDC-E2 immunogenic in a genetically susceptible host.
UNLABELLED: Antimitochondrial antibodies (AMAs) directed against the lipoyl domain of the E2 subunit of pyruvate dehydrogenase (PDC-E2) are detected in 95% of patients with primary biliary cirrhosis (PBC) and are present before the onset of clinical disease. The recent demonstration that AMAs recognize xenobiotic modified PDC-E2 with higher titers than native PDC-E2 raises the possibility that the earliest events involved in loss of tolerance are related to xenobiotic modification. We hypothesized that reactivity to such xenobiotics would be predominantly immunoglobulin M (IgM) and using sera from a large cohort of PBCpatients and controls (n = 516), we examined in detail sera reactivity against either 6,8-bis(acetylthio) octanoic acid (SAc)-conjugated bovineserum albumin (BSA), recombinant PDC-E2 (rPDC-E2) or BSA alone. Further, we also defined the relative specificity to the SAc moiety using inhibition enzyme-linked immunosorbent assay (ELISA); SAc conjugate and rPDC-E2-specific affinity-purified antibodies were also examined for antigen specificity, isotype, and crossreactivity. Reactivity to SAc conjugates is predominantly IgM; such reactivity reflects a footprint of previous xenobiotic exposure. Indeed, this observation is supported by both direct binding, crossreactivity, and inhibition studies. In both early and late-stage PBC, the predominant Ig isotype to SAc is IgM, with titers higher with advanced stage disease. We also note that there was a higher level of IgM reactivity to SAc than to rPDC-E2 in early-stage versus late-stage PBC. Interestingly, this finding is particularly significant in light of the structural similarity between SAc and the reduced form of lipoic acid, a step which is similar to the normal physiological oxidation of lipoic acid. CONCLUSION: Specific modifications of the disulfide bond within the lipoic-acid-conjugated PDC-E2 moiety, i.e., by an electrophilic agent renders PDC-E2 immunogenic in a genetically susceptible host.
Authors: S A Long; C Quan; J Van de Water; M H Nantz; M J Kurth; D Barsky; M E Colvin; K S Lam; R L Coppel; A Ansari; M E Gershwin Journal: J Immunol Date: 2001-09-01 Impact factor: 5.422
Authors: Kiran Bambha; W Ray Kim; Jayant Talwalkar; Heidi Torgerson; Joanne T Benson; Terry M Therneau; Edward V Loftus; Barbara P Yawn; E Rolland Dickson; L Joseph Melton Journal: Gastroenterology Date: 2003-11 Impact factor: 22.682
Authors: Patrick S C Leung; Chao Quan; Ogyi Park; Judy Van de Water; Mark J Kurth; Michael H Nantz; Aftab A Ansari; Ross L Coppel; Kit S Lam; M Eric Gershwin Journal: J Immunol Date: 2003-05-15 Impact factor: 5.422
Authors: Sylvaine F A Bruggraber; Patrick S C Leung; Katsushi Amano; Chao Quan; Mark J Kurth; Michael H Nantz; Gordon D Benson; Judy Van de Water; Velimer Luketic; Thomas E Roche; Aftab A Ansari; Ross L Coppel; M Eric Gershwin Journal: Gastroenterology Date: 2003-12 Impact factor: 22.682
Authors: Glinda S Cooper; Christine G Parks; Edward L Treadwell; E William St Clair; Gary S Gilkeson; Mary Anne Dooley Journal: J Rheumatol Date: 2004-10 Impact factor: 4.666
Authors: Gordon D Benson; Kentaro Kikuchi; Hiroshi Miyakawa; Atsushi Tanaka; Mitchell R Watnik; M Eric Gershwin Journal: Clin Dev Immunol Date: 2004-06
Authors: Zongwen Shuai; Jinjun Wang; Madhu Badamagunta; Jinjung Choi; Guoxiang Yang; Weici Zhang; Thomas P Kenny; Kathryn Guggenheim; Mark J Kurth; Aftab A Ansari; John Voss; Ross L Coppel; Pietro Invernizzi; Patrick S C Leung; M Eric Gershwin Journal: Hepatology Date: 2017-03-31 Impact factor: 17.425
Authors: Toshihiro Tanaka; Weici Zhang; Ying Sun; Zongwen Shuai; Asiya Seema Chida; Thomas P Kenny; Guo-Xiang Yang; Ignacio Sanz; Aftab Ansari; Christopher L Bowlus; Gregory C Ippolito; Ross L Coppel; Kazuichi Okazaki; Xiao-Song He; Patrick S C Leung; M Eric Gershwin Journal: Hepatology Date: 2017-07-20 Impact factor: 17.425
Authors: Patrick S C Leung; Jinjung Choi; Guoxiang Yang; Elena Woo; Thomas P Kenny; M Eric Gershwin Journal: Expert Rev Mol Diagn Date: 2016-03-30 Impact factor: 5.225
Authors: C-H Chang; Y-C Chen; Y-H Yu; M-H Tao; P S C Leung; A A Ansari; M E Gershwin; Y-H Chuang Journal: Clin Exp Immunol Date: 2014-08 Impact factor: 4.330